Dipping rupee to boost FY19 pharma revenues but …
Smart companies will focus on discovering avenues which lead to long-term sustainable growth
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Editor’s note
Competition watch dog raps pharma sector for non-competitive market moves
While the Competition Commission of India (CCI) note appreciates 'legitimate public policy objectives', it tries to determine the…
The pharma play in Ayushman Bharat
With saturation in export markets and rising regulatory constraints, will we see a refocus on the domestic market, prodded by…
India’s FDC saga and other stories
Framing regulations is one thing, interpreting and implementing them quite another saga, allowing repeat offenders like Biomed to…
Putting the bite into our laws
The recent faulty hip implant episode proves that our laws have not evolved as fast as medical technology
Revitalising pharmacy education
While there are good intentions, it is the implementation which threatens the viability of initiatives like the Pharm D course…
Playing for global stakes
Most bigger pharma companies have moved to the next level of exports: the trade of intellectual property, in the form of clinical…
Will indigenisation, innovation and information lead to true independence?
In my Editors Note in last year's Independence Day special issue, I had asked: as we mark our 71st Independence Day this August…
Acing the value chain
It is ironical that a Chinese movie seems to have done what India's policy makers have been trying to do for many years: get China…
Cracking down on fake medicines
One of the important proposals considered during the 79th Drug Technical Advisory Board (DTAB) meeting held on May 16 was the…
Halol haze lifts, finally
It’s time to count the learnings from Halol, both internally for Sun Pharma as well as for India Pharma Inc
Putting all patients first
In a speech on May 12, US President Donald Trump put one of his most populist election promises — to make medicines more…
Diving deeper into pharma GMP
For the past two years, the May 16-31 edition of Express Pharma has been a GMP Special issue, highlighting topics crucial to…
Lessons from Orchid Pharma’s story
The task force on APIs is too late to rescue Orchid Pharma but will hopefully prevent more API makers from burning out.
Mozambique tightens pharma export process
From March 15, Mozambique mandated pre shipment testing of pharma exports, choosing to start with India, which is its largest…
Yet another go at FDCs?
We seem to be slowly but surely moving towards the Centre’s goal of substituting branded medicines with generics
Going beyond cosmetic changes
The 40 odd transfers of drug inspectors/ technical officers that followed Dr Eswara Reddy's appointment as DCG(I) have not…
A spring cleaning at the CDSCO?
February saw a fairly massive churn in India's drug regulatory infrastructure
India Pharma Inc’s place in Modicare
Pharma companies will have to come up with strategies to play a meaningful role in the NHPS
Countering India Pharma Inc’ Achilles heel
India’s drug regulator, the Drug Controller General India (DCGI), should be cheered by a recent report from India Ratings and…